The metabolic landscape of RAS-driven cancers from biology to therapy
S Mukhopadhyay, MG Vander Heiden, F McCormick - Nature cancer, 2021 - nature.com
S Mukhopadhyay, MG Vander Heiden, F McCormick
Nature cancer, 2021•nature.comOur understanding of how the RAS protein family, and in particular mutant KRAS, promotes
metabolic dysregulation in cancer cells has advanced substantially over the last decade. In
this Review, we discuss the metabolic reprogramming mediated by oncogenic RAS in
cancer and elucidate the underlying mechanisms that could translate to novel therapeutic
opportunities to target metabolic vulnerabilities in RAS-driven cancers.
metabolic dysregulation in cancer cells has advanced substantially over the last decade. In
this Review, we discuss the metabolic reprogramming mediated by oncogenic RAS in
cancer and elucidate the underlying mechanisms that could translate to novel therapeutic
opportunities to target metabolic vulnerabilities in RAS-driven cancers.
Abstract
Our understanding of how the RAS protein family, and in particular mutant KRAS, promotes metabolic dysregulation in cancer cells has advanced substantially over the last decade. In this Review, we discuss the metabolic reprogramming mediated by oncogenic RAS in cancer and elucidate the underlying mechanisms that could translate to novel therapeutic opportunities to target metabolic vulnerabilities in RAS-driven cancers.
nature.com